Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.
- Mechanism
- Curator reviewed
NV1FGF is a novel pCOR DNA plasmid–based gene delivery system for local expression of FGF-1. The pCOR plasmid backbone has several features that increase biosafety. These attributes include replication in only a narrow host range of laboratory, but not wild type, Escherichia coli strains, absence of an antibiotic-resistance gene, and lack of the potentially immunostimulatory sequence motifs found in ColE1 plasmids. Preclinical studies of intramuscular administration of NV1FGF have demonstrated that local expression of FGF-1 persists for several weeks. The angiogenic effect of NV1FGF was confirmed in the more severe animal model. The administration of NV1FGF in the hypercholesterolemic hamster model of hindlimb ischemia significantly enhanced the formation of large conductance vessels as well as small resistance arteries in ischemia-injured muscles.
- Primary indication
- Investigated for use/treatment in amputation (limb) and peripheral vascular disease.Curator reviewed
- Also known as
- Non-viral fibroblast growth factor 1 · NV1FGF
- Code names
- XRP0038
Resolves to
What you can answer from here — as of February 21, 2021
Which companies are running trials of Riferminogene pecaplasmid, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account